Drug Trial Radar · NCT06378268
PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study)
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
626
Planned (sponsor's estimate)
Start
Apr 24, 2024
Primary completion
Jun 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Mỹ Đức HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 22, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This non-inferiority randomized controlled trial will be conducted at My Duc Hospital, Ho Chi Minh City, Vietnam. This study compares the effectiveness of Progestin-Primed Ovarian stimulation versus GnRH protocol for ovarian stimulation in IVF treatment. Participants will be randomly assigned in a 1:1 ratio to receive Progestins or GnRH antagonists.
Conditions
- Progestins Primed Ovarian Stimulation
Interventions
Dydrogesterone 10 mgDrug
Dydrogesterone 10mg orally 2 times daily, starting on the day of gonadotropin injection to the oocyte maturation trigger night.
Cetrorelix 0.25 mgDrug
Cetrorelix 0.25mg is injected subcutaneously once a day. It is given from day 5 or day 6 of stimulation by the oocyte maturation trigger day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ongoing pregnancyTime frame: At 10 weeks after embryo(s) placement
Locations
1 site in 1 country. Site status is shown where the registry gives one.
My Duc Hospital
Ho Chi Minh City, Ho Chi Minh City, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.